The Fort Worth Press - Frenchman rewarded for lifetime of research into narcolepsy

USD -
AED 3.672962
AFN 65.000396
ALL 79.569641
AMD 363.410009
ANG 1.790365
AOA 918.000118
ARS 1512.732505
AUD 1.403509
AWG 1.8
AZN 1.684438
BAM 1.695609
BBD 2.01466
BDT 123.160418
BGN 1.683441
BHD 0.377012
BIF 2995
BMD 1
BND 1.273738
BOB 10.998357
BRL 5.144046
BSD 1.000308
BTN 95.98391
BWP 13.567066
BYN 3.037656
BYR 19600
BZD 2.011747
CAD 1.39515
CDF 2309.999597
CHF 0.819885
CLF 0.024143
CLP 953.330119
CNY 6.706399
CNH 6.706796
COP 3133.79
CRC 447.438348
CUC 1
CUP 26.5
CVE 95.999895
CZK 21.106303
DJF 177.71991
DKK 6.489345
DOP 58.850154
DZD 133.63037
EGP 52.199498
ERN 15
ETB 160.949926
EUR 0.86806
FJD 2.21295
FKP 0.741937
GBP 0.744595
GEL 2.603264
GGP 0.741937
GHS 11.505024
GIP 0.741937
GMD 73.99969
GNF 8795.314945
GTQ 7.636255
GYD 209.277425
HKD 7.844805
HNL 26.847168
HRK 6.531703
HTG 130.738787
HUF 316.004029
IDR 17690
ILS 3.027501
IMP 0.741937
INR 95.90965
IQD 1310.5
IRR 1374600.000237
ISK 121.320336
JEP 0.741937
JMD 157.856864
JOD 0.708988
JPY 155.228505
KES 129.498728
KGS 87.449898
KHR 4050.422208
KMF 427.000462
KPW 900.000318
KRW 1367.705023
KWD 0.30856
KYD 0.833583
KZT 444.773881
LAK 22392.336201
LBP 89575.662472
LKR 331.544497
LRD 173.548166
LSL 16.285389
LTL 2.95274
LVL 0.60489
LYD 6.345021
MAD 9.466964
MDL 17.439779
MGA 4325.19127
MKD 53.344315
MMK 2099.62457
MNT 3595.075141
MOP 8.082447
MRU 40.060447
MUR 47.290412
MVR 15.410502
MWK 1736.502094
MXN 17.15007
MYR 4.068397
MZN 63.892219
NAD 16.285247
NGN 1326.720329
NIO 36.811146
NOK 9.361295
NPR 153.579928
NZD 1.739085
OMR 0.384497
PAB 1.000282
PEN 3.355918
PGK 4.522953
PHP 62.724028
PKR 277.25311
PLN 3.781535
PYG 5918.765443
QAR 3.636395
RON 4.568901
RSD 101.865037
RUB 84.244494
RWF 1475.913668
SAR 3.753075
SBD 8.03625
SCR 14.650196
SDG 601.50092
SEK 9.78923
SGD 1.274225
SHP 0.742225
SLE 24.640299
SLL 20969.491881
SOS 571.673797
SRD 37.752497
STD 20697.981008
STN 21.240534
SVC 8.752834
SYP 13002.000254
SZL 16.283395
THB 33.282013
TJS 9.226022
TMT 3.5
TND 2.928519
TOP 2.40776
TRY 48.657898
TTD 6.782056
TWD 31.792499
TZS 2645.002985
UAH 44.609389
UGX 3916.077853
UYU 40.244484
UZS 11793.315705
VES 841.183975
VND 25998.5
VUV 118.157011
WST 2.736734
XAF 569.409897
XAG 0.01559
XAU 0.000231
XCD 2.70255
XCG 1.802758
XDR 0.707052
XOF 569.409897
XPF 103.393717
YER 236.499459
ZAR 16.289965
ZMK 9001.251421
ZMW 19.630588
ZWL 321.999592
SSP 5655.283496
MXV 1.944584
  • CMSC

    0.1600

    20.48

    +0.78%

  • JRI

    -0.1200

    11.5

    -1.04%

  • BCC

    -0.6200

    75.31

    -0.82%

  • BTI

    -0.4300

    56.09

    -0.77%

  • BCE

    -0.4000

    22.5

    -1.78%

  • GSK

    0.2800

    50.29

    +0.56%

  • RIO

    -1.4700

    95.79

    -1.53%

  • NGG

    1.1000

    76.03

    +1.45%

  • RBGPF

    0.0000

    69.99

    0%

  • BP

    -1.5800

    45.38

    -3.48%

  • RYCEF

    0.2600

    19.3

    +1.35%

  • CMSD

    0.2200

    20.29

    +1.08%

  • RELX

    0.0500

    34.27

    +0.15%

  • AZN

    1.0400

    162.89

    +0.64%

  • VOD

    -0.2200

    17.46

    -1.26%

Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Frenchman rewarded for lifetime of research into narcolepsy

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

T.Harrison--TFWP